Given that numerous RAD52 small molecule inhibitors have been described that may be translatable for use in the clinic [25,27,31], expanding the understanding of when cells become reliant on RAD52 will inform the successful application of such inhibitors in cancer treatment. Here, RAD52 is linked to cancer.